Corcept Therapeutics | CORT - Pre Tax Profit


Corcept Therapeutics reported $-44.72M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 46.47M 42.49M Jun/2026
Alaunos Therapeutics USD -7.84M 633K Dec/2023
ANI Pharmaceuticals USD 40.22M 8.74M Mar/2026
Ardelyx USD -37.6M 37.2M Mar/2026
Aurora Cannabis CAD 11.41M 12.99M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Canopy Growth CAD -157.96M 95.71M Mar/2026
Corcept Therapeutics USD -44.72M 54.62M Mar/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
J&J USD 7.67B 988M Sep/2026
Knight Therapeutics CAD -1.92M 13.69M Sep/2025
Lexicon Pharmaceuticals USD -12.77M 16.02M Sep/2025
Merck USD -3.53B 6.95B Mar/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novartis USD 3.84B 1.33B Mar/2026
Omeros USD -65.12M 21.27M Jun/2024
Pacira USD 5M 4.43M Mar/2026
Pfizer USD -653M 5.84B Jun/2026
Supernus Pharmaceuticals USD -57.65M 51.7M Jun/2026
TG Therapeutics USD 10.23M 10.13M Jun/2026